Is elevated cardiovascular risk a class effect of cyclo-oxygenase 2 inhibitors?
Scott D Solomon
Correspondence Cardiovascular Division, Brigham and Women's Hospital, PBB-175, Francis Street, Boston, MA 02115, USA
Email sdsolomon@bics.bwh.harvard.edu
This article has no abstract so we have provided the first paragraph of the full text.
In 2004, an increased risk of cardiovascular events was observed in a randomized controlled trial of rofecoxib for polyp prevention, leading to discontinuation of that trial, withdrawal of rofecoxib from the market, and a focused review of other agents in this class.1 Within a few months, data showed that celecoxib and valdecoxib were also associated with increased cardiovascular risk.2, 3 Ultimately, these data and a comprehensive FDA review led to a black-box warning for celecoxib, and valdecoxib's withdrawal.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
